This study is in progress, not accepting new patients

TrEatment Approach in the Multimodal Era Registry

a study on Chronic Thromboembolic Pulmonary Hypertension High Blood Pressure Pulmonary Hypertension

Summary

Eligibility
for people ages 18 years and up (full criteria)
Location
at UCSD
Dates
study started
study ends around
Principal Investigator
by Nick H Kim, MD (ucsd)

Description

Summary

The goal of this observational patient registry is to learn how expert centers treat patients with chronic thromboembolic pulmonary hypertension (CTEPH). CTEPH is a condition in which blood clots block the blood vessels in the lungs. There are currently three treatment options for patients with CTEPH:

  • surgery to remove blood clots from large vessels in the lungs (pulmonary endarterectomy (PEA))
  • the use of a small balloon to unblock smaller blood vessels (balloon pulmonary angioplasty (BPA))
  • drugs

Patients can also receive a combination of these treatments.

The main question this registry aims to answer are:

  • How many patients receive a given kind of treatment?
  • How do expert centers combine the different treatments?
  • Are patients doing better after they receive a given kind of treatment?
  • How many patients are alive 1, 3 and 5 years after they receive a given kind of treatment?

Participants will receive the same treatments that they would receive if they did not participate in the study. During the study, patients will visit their doctors as they would do normally. The doctors will collect information on the patients' health and enter it into the study database. The follow-up time will be at least 3 years for all patients.

Keywords

Chronic Thromboembolic Pulmonary Hypertension, CTEPH, Pulmonary endarterectomy, PEA, Balloon pulmonary angioplasty, BPA, Multimodal treatment, Pulmonary Hypertension, Hypertension, Pulmonary hypertension (PH)-specific medication

Eligibility

You can join if…

Open to people ages 18 years and up

  1. Newly referred patient with CTEPH or chronic thromboembolic pulmonary disease (CTEPD) without PH according to the following criteria:
    1. Mean pulmonary arterial pressure (mPAP) > 20 mmHg at rest with pulmonary vascular resistance (PVR) > 2 Wood units (WU); or if mPAP ≤ 20 mmHg or PVR ≤ 2 WU at rest, have exercise limitations from CTEPD without PH
    2. Abnormal ventilation perfusion scan, pulmonary angiogram, computer tomographic pulmonary angiogram, or magnetic resonance pulmonary angiogram confirming CTEPD as recommended by standard guidelines
  2. Treatment with anticoagulation for ≥ 3 months before diagnosis of CTEPH or CTEPD without PH
  3. Naïve to interventional treatment (both PEA and BPA)
  4. Pre-treatment with PH-specific medication for ≤ 12 months, or no medical pre-treatment, at enrollment
  5. Willing and able to provide informed consent in order to participate in the study (informed consent signed)
  6. Age ≥ 18 years
  7. CTEPH-specific treatment must be modified or initiated at the participating site

You CAN'T join if...

  1. Main cause of PH other than CTEPH
  2. Participating in an interventional clinical trial at enrollment

Locations

  • University of California San Diego
    San Diego California 92037 United States
  • UT Southwestern
    Dallas Texas 75390 United States

Lead Scientist at University of California Health

Details

Status
in progress, not accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
International CTEPH Association
Links
Description of the registry on the website of the International CTEPH Association
ID
NCT05629052
Study Type
Observational [Patient Registry]
Participants
Expecting 1000 study participants
Last Updated